Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amylin 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amylin 1Q11

Byetta sales were $128.0 million (-15%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amylin 1Q11

1Q Revenues: $152.7 million (-12%)

1Q Loss: $37.3 million (loss of $38.2 million in 1Q10)

Comments: Byetta sales were $128.0 million (-15%). Collaborative profit sharing, which represents Lilly’s share of Byetta, was $59.9 million for the quarter, compared to $67.9 million for the same period in 2010. Symlin (pramlintide acetate) injection sales were $22.8 million (+1%). Revenues under collaborative agreements were flat at $1.9 million. During the quarter, the company notified its partner Lilly of its intent to draw a $165 million line of credit from Lilly.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters